Experts advising the government voted last week that the drug appears to increase heart risks. They also recommend leaving the Glaxo-Smith-Kline drug on the market for now because the evidence is not definitive.
The Food and Drug Administration is now deciding what action to take. In the meantime, it has put on hold a study of whether Avandia is less safe than its competitor Actos.
